Emerging Strategies for Increasing High-Density Lipoprotein

American Journal of Cardiology

Volumn 98, Issue 11, 2006, Pages 1542-1549

  Forrester, James S ^a   Shah, Prediman K ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO] PHENYL] ESTER; 2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; 2,4 THIAZOLIDINEDIONE DERIVATIVE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MILANO; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CLOFIBRATE; COLESTIPOL; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MURAGLITAZAR; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PRAVASTATIN; RIMONABANT; ROSUVASTATIN; SIMVASTATIN; SYNTHETIC PEPTIDE; TORCETRAPIB; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEPRESSION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; MOOD CHANGE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; HUMANS; LIPOPROTEINS, HDL; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; RISK FACTORS;

EID: 33751181224     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.06.059     Document Type: Review

References (61)

1. Schaefer E.J., Lamon-Fava S., Ordovas J.M., Cohn S.D., Schaefer M.M., Castelli W.P., and Wilson P.W. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-1 levels in the Framingham Offspring Study. J Lipid Res 35 (1994) 871-882
2. Arias E., Anderson R.N., Kung H.-C., Murphy S.L., and Kochanek K.D. Deaths: final data for 2001. Nat Vital Stat Rep 52 (2003) 8-9
3. Ameli S., Hultgardh-Nilsson A., Cercek B., Shah P.K., Forrester J.S., Ageland H., and Nilsson J. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 90 (1994) 1935-1941
4. Shah P.K., Nilsson J., Kaul S., Fishbein M.C., Ageland H., Hamsten A., Johansson J., Karpe F., and Cercek Bl. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97 (1998) 780-785
5. Shah P.K., Yano J., Reyes O., Chyu K.Y., Kaul S., Bisgaier C.L., Drake S., and Cercek B. High-dose recombinant apolipoprotein A-I(Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 103 (2001) 3047-3050
6. Belalcazar L.M., Merched A., Carr B., Oka K., Chen K.H., Pastore L., Beaudet A., and Chan L. Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 107 (2003) 2726-2732
7. Forrester J.S., Makkar R., and Shah P.K. Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 111 (2005) 1847-1854
8. Assmann G., Schulte H., von Eckardstein A., and Huang Y. High density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124 suppl (1996) S11-S20
9. Westman J., Roobol C., Carlson L.A., and Wulfert E. In vitro reverse cholesterol transport from THP-1-derived macrophage-like cells with synthetic HDL particles consisting of proapolipoprotein A1 or apolipoprotein A1 and phosphatidylcholine. Scand J Clin Lab Invest 55 (1995) 23-33
10. Nanjee M.N., Cooke C.J., Garvin R., Semeria F., Lewis G., Olszewski W.L., and Miller N.E. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 42 (2001) 1586-1593
11. Spieker L.E., Sudano I., Hurlimann D., Lerch P.G., Lang M.G., Binggeli C., Corti R., Ruschitzka F., Luscher T.F., and Noll G. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002) 1399-1402
12. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003) 2292-2300
13. Nissen S.E., Nicholls S.J., Sipahi I., Libby P., Raichlen J.S., Ballantyne C.M., Davignon J., Erbel R., Fruchart J.C., Tardif J.C., et al., ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295 (2006) 1556-1565
14. Forrester J.S. Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med 137 (2002) 823-833
15. Shah P.K., Kaul S., Nilsson J., and Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming. Part I. Circulation 104 (2001) 2376-2383
16. Shah P.K., Kaul S., Nilsson J., and Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming. Part II. Circulation 104 (2001) 2498-2502
17. Rader D.J. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 92 suppl (2003) 42J-49J
18. Wang N., Lan D., Chen W., Matsuura F., and Tall A.R. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 101 (2004) 9774-9779
19. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., Vahabzadeh K., Hama S., Hough G., Kamranpour N., et al. Thematic review series: the pathogenesis of atherosclerosis: the oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
20. Reilly K.B., Srinivasan S., Hatley M.E., Patricia M.K., Lannigan J., Bolick D.T., Vandenhoff G., Pei H., Natarajan R., Nadler J.L., and Hedrick C.C. 12/15 lipoxygenase activity mediates inflammatory monocyte:endothelial interactions and atherosclerosis in vivo. J Biol Chem 279 (2004) 9440-9450
21. Navab M., Hama S.Y., Cooke C.J., Anantharamaiah G.M., Chaddha M., Jin L., Subbanagounder G., Faull K.F., Reddy S.T., Miller N.E., and Fogelman A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41 (2000) 1481-1494
22. Mineo C., and Shaul P.W. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 13 (2003) 226-231
23. Perez-Mendez O., Bruckert E., Franceschini G., Duhal N., Lacroix B., Bonte J.P., Sirtori C., Fruchart J.C., Turpin G., and Luc G. Metabolism of apolipoproteins AI and AII in subjects carrying similar apoAI mutations, apoAI Milano and apoAI Paris. Atherosclerosis 148 (2000) 317-325
24. Nagano M., Yamashita S., Hirano K., Takano M., Maruyama T., Ishihara M., Sagehashi Y., Kujiraoka T., Tanaka K., Hattori H., et al. Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb 11 (2004) 110-121
25. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Hama S., Hough G., Bachini E., Grijalva V.R., Wagner A.C., et al. The double jeopardy of HDL. Ann Med 37 (2005) 173-178
26. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., and Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 103 (2001) 2283-2288
27. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
28. Sugano M., Sawada S., Tsuchida K., Makino N., and Kamada M. Low density lipoproteins develop resistance to oxidative modification due to inhibition of cholesteryl ester transfer protein by a monoclonal antibody. J Lipid Res 41 (2000) 126-133
29. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., Pettey C.L., Adari H., Hammond R.A., Beattie D.T., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000) 2106-2112
30. Davidson M.H., Maki K., Umporowicz D., Wheeler A., Rittershaus C., and Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169 (2003) 113-120
31. Schaefer E.J. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol 25 (2005) 1057-1064
32. Matsuura F., Wang N., Chen W., Jiang X.C., and Tall A.R. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J Clin Invest 116 (2006) 1435-1442
33. Okamoto H., Iwamoto Y., Maki M., Sotani T., Yonemori F., and Wakitani K. Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol 466 (2003) 147-154
34. Huang Z., Inazu A., Nohara A., Higashikata T., and Mabuchi H. Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia. Clin Sci 103 (2002) 587-594
35. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105, 2159-2165.
36. Clark R.W., Sutfin T.A., Ruggeri R.B., Willauer A.T., Sugarman E.D., Magnus-Aryitey G., Cosgrove P.G., Sand T.M., Wester R.T., Williams J.A., et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24 (2004) 490-497
37. Brousseau M.E., Schaefer E.J., Wolfe M.L., Bloedon L.T., Digenio A.G., Clark R.W., Mancuso J.P., and Rader D.J. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350 (2004) 1505-1515
38. Soma M.R., Donetti E., Parolini C., Sirtori C.R., Fumagalli R., and Franceschini G. Recombinant apolipoprotein A-I Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res 76 (1995) 405-411
39. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Datta G., Garber D., and Fogelman A.M. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Curr Opin Lipidol 15 (2004) 645-649
40. Li X., Chyu K.Y., Neto J.R., Yano J., Nathwani N., Ferreira C., Dimayuga P.C., Cercek B., Kaul S., and Shah P.K. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110 (2004) 1701-1705
41. Pelton P.D., Patel M., and Demarest K.T. Nuclear receptors as potential targets for modulating reverse cholesterol transport. Curr Top Med Chem 5 (2005) 265-282
42. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586
43. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
44. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., Rosenstock J., and RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006) 761-775
45. Despres J.P., Golay A., Sjostrom L., and Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 (2005) 2121-2134
46. Williams K.J., Scalia R., Mazany K.D., Rodrigueza W.V., and Lefer A.M. Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. Arterioscler Thromb Vasc Biol 20 (2000) 1033-1039
47. Burgess J.W., Boucher J., Neville T.A., Rouillard P., Stamler C., Zachariah S., and Sparks D.L. Phosphatidylinositol promotes cholesterol transport and excretion. J Lipid Res 44 (2003) 1355-1363
48. Burgess J.W., Neville T.A., Rouillard P., Harder Z., Beanlands D.S., and Sparks D.L. Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res 46 (2005) 350-355
49. Superko H.R. The failure of LDL cholesterol reduction and the importance of reverse cholesterol transport. The role of nicotinic acid. Br J Card 13 (2006) 131-136
50. Manninen V., Elo O., Frick H., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., and Koskinen P. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260 (1988) 641-651
51. Robins S.J., Collins D., Wittes J.T., Papademetriou V., Deedwania P.C., Schaefer E.J., McNamara J.R., Kashyap M.L., Hershman J.M., Wexler L.F., Rubins H.B., and VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
52. The BIP Investigators. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102 (2000) 21-27
53. Ruotolo G., Ericsson C.G., Tettamanti C., Karpe F., Grip L., Svane B., Nilsson J., de Faire U., and Hamsten A. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 32 (1998) 1648-1656
54. Frick M.H., Syvanne M., Nieminen M.S., Kauma H., Majahalme S., Virtanen V., Kesaniemi Y.A., Pasternack A., Taskinen M.R., and Lopid Coronary Angiography Trial (LOCAT) Study Group. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 96 (1997) 2137-2143
55. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357 (2001) 905-910
56. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 231 (1975) 360-381
57. Carlson L.A., Danielson M., Ekberg I., Klintemar B., and Rosenhamer G. Reduction of myocardial reinfarction by the combined treatment with clofibrate and nicotinic acid. Atherosclerosis 28 (1977) 81-86
58. Blankenhorn D.H., Azen S.P., Crawford D.W., Nessim S.A., Sanmarco M.E., Selzer R.H., Shircore A.M., and Wickham E.C. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 83 (1991) 438-447
59. Stewart B.F., Brown B.G., Zhao X.Q., Hillger L.A., Sniderman A.D., Dowdy A., Fisher L.D., and Albers J.J. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol 23 (1994) 899-906
60. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 (2001) 1583-1592
61. Taylor A.J., Sullenberger L.E., Lee H.J., Lee J.K., and Grace K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110 (2004) 3512-3517